|
Título:
|
Antiepileptic drug therapy and recommendations for withdrawal in patients with seizures and epilepsy due to neurocysticercosis
|
|
Autores:
|
Bustos, Javier-A. ;
Garcia, Hector-H. ;
Del-Brutto, Oscar-H.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Taylor & Francis, 2019-02-06T14:51:17Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
INTRODUCTION: Neurocysticercosis (NCC) is a leading causes of secondary epilepsy worldwide. There is increasing evidence on the epileptogenic role of NCC, and the presence of edema, calcified scars, gliosis and hippocampal sclerosis support this phenomenon. AREAS COVERED: We summarized principles of antiepileptic drug (AED) therapy as well as risk factors associated with seizure recurrence after AED withdrawal in patients with NCC. Expert commentary: First-line AED monotherapy is effective as a standard approach to control seizures in most NCC patients. Risks and benefits of AED withdrawal have not been systematically studied, and this decision must be individualized. However, a seizure-free period of at least two years seem prudent before attempting withdrawal. Risk factors for seizure recurrence after AED withdrawal include a history of status epilepticus, poor seizure control during treatment, neuroimaging evidence of perilesional gliosis, hippocampal sclerosis and calcified lesions, as well as persistence of paroxysmal activity in the EEG.
|
|
En línea:
|
http://doi.org/10.1080/14737175.2016.1194757
|
